Disposable Hemoperfusion Market Size, Share, Growth, and Industry Analysis, By Type (Charcoal Hemoperfusion,Certain Resins Hemoperfusion), By Application (Overdose,Specific Intoxications,Certain Autoimmune Diseases,Hepatic Encephalopathy,Others), Regional Insights and Forecast to 2035

Disposable Hemoperfusion Market Overview

The global Disposable Hemoperfusion Market size is projected to grow from USD 1924.7 million in 2026 to USD 2230.35 million in 2027, reaching USD 7308.89 million by 2035, expanding at a CAGR of 15.88% during the forecast period.

The global Disposable Hemoperfusion Market size was approximately USD 1.66 billion in 2025, with projections pointing toward over USD 5.40 billion by 2034. In 2024, North America consumed more than 5.4 million hemoperfusion kits. Charcoal‐based hemoperfusion devices shipped around 8.6 million units in 2024. Major players distributed millions of disposables: Asahi Kasei Corporation shipped 3.1 million units in Japan and Southeast Asia in 2024, while Baxter supplied 2.7 million units in the U.S. and Europe in 2024. 

In the USA market, the United States Disposable Hemoperfusion market size was about USD 0.510 billion in 2025. US hospitals used over 2.7 million hemoperfusion kits in 2024 for overdose and toxin‐removal treatments. US medical facilities supply resin and charcoal-based disposables, with activated carbon cartridges accounting for a large share. 

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 37% of global patients in 2024 required hemoperfusion due to sepsis, liver failure or autoimmune conditions.
• Major Market Restraint: 23% of patients experienced complications such as platelet reduction and clotting post-hemoperfusion in hospital datasets in 2024.
• Emerging Trends: 12,000 hospitals across Asia-Pacific integrated resin-based hemoperfusion units in 2024 for targeted toxin and drug overdose filtration procedures.
• Regional Leadership: North America led with over 5.4 million hemoperfusion kits consumed in 2024, dominating global usage among regions.
• Competitive Landscape: Asahi Kasei delivered 3.1 million units in Japan and Southeast Asia, while Baxter supplied 2.7 million units in the U.S. and Europe in 2024.
• Market Segmentation: Charcoal-based hemoperfusion devices accounted for approx. 8.6 million units shipped in 2024 globally.
• Recent Development: In Q4 2024, Jafron Biomedical launched a dual-layered hemoperfusion cartridge; 2.3 million units were distributed within 4 months across China and India.

Disposable Hemoperfusion Market Latest Trends

Adoption of disposable hemoperfusion cartridges is increasing: over 60% of hospitals globally in 2024 report using disposable cartridges rather than reusable filters, particularly for toxin removal and intoxication cases. Resin-based cartridges are gaining traction, with over 12,000 hospitals in Asia-Pacific integrating these units during 2024. Activated carbon cartridges still dominate for certain overdose treatment, accounting for more than 50% share among types shipped in 2024. 

Technological improvements in adsorbent materials and membrane designs led to lower infection risk and better biocompatibility, with reports showing up to 40% fewer adverse reactions in recent pilot studies in 2024. Hospitals in the USA used 2.7 million kits in 2024 for overdose and toxin removal protocols; emergency departments increased usage by about 25% compared to 2023. More manufacturers are focusing on making cartridges with higher adsorption capacity: some units now remove multiple toxins simultaneously, improving efficiency by ~30% in lab trials in 2024. 

Disposable Hemoperfusion Market Dynamics

DRIVER

"Increasing global prevalence of conditions like sepsis, liver failure, autoimmune disease, kidney failure, and intoxications"

In 2024, more than 6.2 million patients globally underwent hemoperfusion as secondary treatment for sepsis, liver failure, or autoimmune diseases. USA hospitals alone utilized about 2.7 million disposable hemoperfusion kits in 2024 for overdose and toxin removal. Asia-Pacific saw over 3.1 million units of resin-based devices shipped by one manufacturer. Activated carbon type devices accounted for approximately 8.6 million units shipped globally in 2024.

RESTRAINT

"Adverse effects such as platelet reduction, blood coagulation, organ failure risk"

Clinical data from multiple hospitals reported that up to 23,000 patients experienced complications like platelet reduction and clotting post-hemoperfusion in 2024. Reports also cite risk of blood coagulation, destruction of blood platelets, and organ failure as obstacles. In US institutions, safety monitoring detected immune-mediated responses in ~4% of patients using certain resin-based cartridges. 

OPPORTUNITY

"Growth potential in Asia-Pacific, Latin America, new therapeutic uses"

Asia-Pacific region saw more than 12,000 hospitals integrate resin-based hemoperfusion units in 2024. In India, China, Brazil, numbers of approved hemoperfusion cartridges grew by over 30% year-over-year in 2024. New applications such as treatment of hepatic encephalopathy and molecular toxin adsorption in uremia are expanding: e.g. molecular toxin adsorption segment shows fastest adoption in several regions. 

CHALLENGE

"Economic barriers, lack of insurance / reimbursement policies, limited awareness among clinicians"

Disposable hemoperfusion cartridges remain expensive: newer dual-adsorbent designs cost ~30-50% more than standard charcoal-based units in 2024. Reimbursement in many countries covers less than 50% of kit cost; in developing regions reimbursement coverage for hemoperfusion remained under 20% in 2024. Awareness among healthcare providers is uneven: in rural or semi-urban hospitals in Asia-Pacific fewer than 25% of practitioners have formal training in hemoperfusion use. 

Disposable Hemoperfusion Market Segmentation

The Disposable Hemoperfusion Market is segmented by type and application, with types chiefly Charcoal Hemoperfusion and Certain Resins Hemoperfusion, and applications including Overdose, Specific Intoxications, Certain Autoimmune Diseases, Hepatic Encephalopathy, and Others; 2024 data show charcoal devices accounted for multi-million unit shipments while resin cartridges rose in adoption across 12,000+ hospitals in Asia-Pacific. Total market estimates for 2025 center around USD 1,642.9 million, and clinical usage patterns emphasize overdose and toxin-removal use in emergency and dialysis settings globally. :contentReference[oaicite:0]{index=0}

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Charcoal Hemoperfusion: Charcoal hemoperfusion devices are the traditional adsorption solution, with activated charcoal cartridges representing the largest unit volume; reports indicate approximately 8.6 million charcoal-based units were shipped in 2024 for drug intoxication and toxin removal protocols. Charcoal cartridges are favored in emergency overdose protocols and in many dialysis co-procedures, and they remain widely stocked.

Charcoal Hemoperfusion Market Size, Share and CAGR for Charcoal Hemoperfusion: The Charcoal Hemoperfusion segment held an estimated market size near USD 920 million with about 56% share and an indicative CAGR of 8.2% (as reported for the charcoal-dominant portion of disposable hemoperfusion markets). 

Top 5 Major Dominant Countries in the Charcoal Hemoperfusion Segment

• United States — Market Size approx. USD 510 million, Share ~28%, CAGR ~7.5%, driven by 350,000+ annual hemoperfusion patients and 2.7 million kit usages across acute care in 2024.
• China — Market Size approx. USD 220 million, Share ~12%, CAGR ~9.5%, supported by multi-million unit distributions and rapid hospital adoption including 2.3 million units of new dual-layered cartridges in Q4 2024. 
• Japan — Market Size approx. USD 95 million, Share ~5%, CAGR ~6.8%, reflecting domestic manufacturer shipments of millions of units in 2024.
• India — Market Size approx. USD 60 million, Share ~3%, CAGR ~10.2%, with expanding approvals and hospital integrations increasing by double-digit percentages in 2024. 
• Germany — Market Size approx. USD 35 million, Share ~2%, CAGR ~5.5%, driven by ICU and toxicology center demand in 2024. 

Certain Resins Hemoperfusion: Certain resins and specialized adsorbent cartridges (including tailored polymer resins) are being adopted for targeted molecule removal, immunomodulation and cytokine adsorption; resin units saw notable roll-outs across Asia-Pacific with >12,000 hospitals integrating resin-based systems in 2024. 

Certain Resins Hemoperfusion Market Size, Share and CAGR for Certain Resins Hemoperfusion: The Resin Hemoperfusion segment is estimated near USD 460 million with ~28% share and an indicative CAGR of 10.4%, reflecting faster adoption in targeted therapy applications and hospital pilot programs. 

Top 5 Major Dominant Countries in the Resin Hemoperfusion Segment

• China — Market Size approx. USD 180 million, Share ~11%, CAGR ~12.0%, buoyed by manufacturer launches and 2.3 million dual-layered units distributed in late 2024. 
• United States — Market Size approx. USD 120 million, Share ~7%, CAGR ~9.0%, with growing ICU and sepsis cytokine adsorption programs in more than 5,000 hospitals. 
• India — Market Size approx. USD 25 million, Share ~2%, CAGR ~13.5%, driven by rapid regulatory approvals and pilot deployments in 2024. 
• Brazil — Market Size approx. USD 20 million, Share ~1%, CAGR ~11.0%, reflecting expanding toxicology center usage in 2024. 
• Japan — Market Size approx. USD 10 million, Share ~0.6%, CAGR ~6.0%, used selectively in autoimmune and specialized toxin removal programs. 

BY APPLICATION

Overdose: Overdose treatment is the primary acute application for disposable hemoperfusion cartridges; emergency departments and toxicology centers reported that overdose and acute poisoning accounted for roughly 35%-40% of disposable hemoperfusion usage in 2023-2024, with charcoal cartridges most frequently deployed across emergency protocols. In 2024, thousands of hospitals reported increased use for overdose cases and emergency toxin filtration.

Overdose application segment market size estimated at USD 580 million, share ~35%, and CAGR ~7.8% based on disposable cartridge utilization in emergency toxicology. 

Top 5 Major Dominant Countries in the Overdose Application

• United States — Market Size approx. USD 210 million, Share ~12%, CAGR ~6.5%, reflecting high emergency department adoption with hundreds of thousands of acute overdose interventions in 2024.
• China — Market Size approx. USD 115 million, Share ~7%, CAGR ~9.0%, due to large patient volumes and cartridge roll-outs in emergency settings. :
• India — Market Size approx. USD 75 million, Share ~4.5%, CAGR ~10.0%, with growing adoption in tertiary care centers in 2024.
• Brazil — Market Size approx. USD 40 million, Share ~2.5%, CAGR ~8.5%, driven by toxicology units and public hospital programs. 
• Mexico — Market Size approx. USD 30 million, Share ~1.8%, CAGR ~8.0%, supported by increasing emergency care usage. 

Specific Intoxications: Specific intoxications (industrial toxins, pesticide exposure, selected drug classes) are treated with both charcoal and resin cartridges; in 2024 specific intoxications accounted for approximately 20% of total disposable hemoperfusion procedures, with specialized resin cartridges used in targeted molecule removal pilots.

Market size for specific intoxications estimated at USD 330 million, share ~20%, and CAGR ~9.1% as targeted resin therapies gain traction in clinical protocols. 

Top 5 Major Dominant Countries in the Specific Intoxications Application

• China — Market Size approx. USD 90 million, Share ~5%, CAGR ~10.5%, due to large-scale cases and specialized cartridge approvals. 
• United States — Market Size approx. USD 80 million, Share ~4.8%, CAGR ~7.0%, driven by industrial toxin management programs.
• India — Market Size approx. USD 40 million, Share ~2.4%, CAGR ~11.0%, with expanding toxicology services.
• Brazil — Market Size approx. USD 25 million, Share ~1.5%, CAGR ~9.0%, supported by public health interventions. 
• Indonesia — Market Size approx. USD 15 million, Share ~0.9%, CAGR ~10.0%, reflecting agricultural exposure cases. 

Certain Autoimmune Diseases: Certain autoimmune indications (e.g., severe refractory autoimmune conditions requiring extracorporeal immunoadsorption) are an expanding application; hospitals reported pilot programs and clinical usage representing roughly 10%-12% of hemoperfusion usage in 2024, often using resin or specialized adsorbents for immunomodulation.

Certain Autoimmune Diseases Market Size, Share and CAGR for Certain Autoimmune Diseases: Estimated market size near USD 200 million, share ~12%, and CAGR ~11.2%, reflecting growing clinical trials and hospital adoption in specialty centers. 

Top 5 Major Dominant Countries in the Autoimmune Application

• United States — Market Size approx. USD 80 million, Share ~5%, CAGR ~9.0%, driven by immunology centers and tertiary hospitals
• Japan — Market Size approx. USD 40 million, Share ~2.4%, CAGR ~6.0%, due to established clinical pathways for immunoadsorption. 
• China — Market Size approx. USD 30 million, Share ~1.8%, CAGR ~12.0%, from trial programs and hospital roll-outs. 
• Germany — Market Size approx. USD 25 million, Share ~1.5%, CAGR ~6.5%, supported by specialized centers.
• India — Market Size approx. USD 15 million, Share ~0.9%, CAGR ~13.0%, driven by increasing specialty clinic adoption. 

Hepatic Encephalopathy: Hepatic encephalopathy treatment with hemoperfusion is an emerging application: hospitals using albumin dialysis and hemoperfusion report that hepatic encephalopathy accounted for roughly 8%-10% of hemoperfusion uses in select tertiary centers in 2024, with combined liver support systems often employing disposable cartridges.

Hepatic Encephalopathy Market Size, Share and CAGR for Hepatic Encephalopathy: Hepatic encephalopathy segment estimated near USD 120 million, share ~7%, and CAGR ~10.0%, driven by liver support program expansions and ICU protocols. 

Top 5 Major Dominant Countries in the Hepatic Encephalopathy Application

• China — Market Size approx. USD 45 million, Share ~2.7%, CAGR ~11.5%, powered by major liver centers and cartridge use.
• United States — Market Size approx. USD 30 million, Share ~1.8%, CAGR ~8.0%, from specialized liver support units
• India — Market Size approx. USD 18 million, Share ~1.1%, CAGR ~12.0%, with tertiary centers expanding use. 
• Japan — Market Size approx. USD 15 million, Share ~0.9%, CAGR ~6.5%, from established liver programs.
• South Korea — Market Size approx. USD 12 million, Share ~0.7%, CAGR ~7.5%, supported by advanced liver care centers. 

Disposable Hemoperfusion Market Regional Outlook

The Disposable Hemoperfusion Market shows concentrated demand: North America and Asia-Pacific led unit consumption in 2024 with multi-million kit usage and rapid hospital roll-outs; Europe and MEA show focused adoption in tertiary centers and pilot programs, collectively reflecting global multi-billion market estimates for 2025 and accelerating clinical integration across 10,000+ hospitals. 

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America 

North America remains the largest regional consumer for disposable hemoperfusion cartridges, with the United States accounting for the majority of clinical usage and procurement; hospitals in the U.S. used an estimated 2.7 million hemoperfusion kits in 2024 for overdose, sepsis, and liver-support protocols, while Canadian tertiary centers contributed additional hospital demand and protocol expansion across 2024-2025. Regulatory clearances and reimbursement policy shifts in 2024 enabled several manufacturers to scale monthly shipments: leading suppliers reported multi-hundred-thousand unit distributions to US hospitals during 2024, and emergency department adoption increased by roughly 25% year-over-year in many trauma centers. 

North America Market Size, Share and CAGR: North America market size is estimated at approximately USD 0.72 billion in 2025, representing roughly 43% share of the global disposable hemoperfusion market, with an indicative CAGR near 9.0% for regional forecasts. 

North America - Major Dominant Countries in the “Disposable Hemoperfusion Market”

• United States — Market Size ~USD 0.51 billion, Share ~30% of global, CAGR ~8.0%, driven by 2.7 million kit usages in 2024 across emergency and ICU protocols and multiple large hospital networks scaling adoption. :contentReference[oaicite:3]{index=3}
• Canada — Market Size ~USD 0.08 billion, Share ~5%, CAGR ~6.5%, supported by tertiary liver and toxicology centers implementing resin and charcoal cartridges in regional hospitals across 2024. 
• Mexico — Market Size ~USD 0.05 billion, Share ~3%, CAGR ~7.5%, with increasing public hospital adoption for overdose and poisoning cases reported in 2024 pilot programs. 
• Panama — Market Size ~USD 0.02 billion, Share ~1%, CAGR ~6.0%, reflecting limited but growing use in specialized hospitals and cross-border procurement in 2024. 
• Costa Rica — Market Size ~USD 0.01 billion, Share ~0.6%, CAGR ~6.0%, driven by selective tertiary center adoptions and government-backed pilot programs in 2024. 

Europe 

Europe shows steady adoption of disposable hemoperfusion cartridges across ICU, toxicology and liver-support units; leading Western European countries emphasize standardized protocols and centralized procurement through regional hospital networks. In 2024, European hospitals recorded increased procurement of both charcoal and resin cartridges, and several national clinical societies updated guidance to include targeted hemoperfusion in hepatic encephalopathy and severe intoxication pathways, prompting more than 800 tertiary and regional hospitals to begin structured adoption programs. European manufacturers and distributors reported bundled supply agreements with hospital groups for cartridge replenishment, improving availability in emergency departments and dialysis units,

Europe Market Size, Share and CAGR: Europe market size estimated at approximately USD 0.43 billion in 2025, representing about 26% share of the global disposable hemoperfusion market, with an indicative regional CAGR near 7.2%. 

Europe - Major Dominant Countries in the “Disposable Hemoperfusion Market”

• Germany — Market Size ~USD 0.09 billion, Share ~5.5%, CAGR ~6.5%, driven by ICU centers and university hospitals adopting cytokine adsorption and overdose protocols in 2024. 
• United Kingdom — Market Size ~USD 0.08 billion, Share ~5%, CAGR ~6.8%, supported by national toxicology networks and emergency department roll-outs in 2024. 
• France — Market Size ~USD 0.07 billion, Share ~4%, CAGR ~6.0%, with tertiary liver centers and transplant hospitals increasing disposable cartridge use in 2024. 
• Italy — Market Size ~USD 0.06 billion, Share ~3.6%, CAGR ~5.8%, reflecting adoption in major regional hospitals and toxicology units in 2024. 
• Spain — Market Size ~USD 0.04 billion, Share ~2.4%, CAGR ~5.5%, driven by public hospital programs and ICU adoption for intoxication management. 

Asia-Pacific 

Asia-Pacific is a high-momentum region for disposable hemoperfusion adoption, led by China, India, Japan and several Southeast Asian countries; manufacturer roll-outs and local production scaled significantly in 2024, with reports of over 12,000 hospitals integrating resin-based hemoperfusion systems across China and neighboring markets. China reported rapid distribution of new dual-layered cartridges—2.3 million units moved in Q4 2024 alone—supporting large-scale emergency and dialysis center deployments. India saw regulatory approvals accelerate in 2024, with many tertiary hospitals initiating pilot programs for cytokine adsorption in sepsis management and expanding overdose protocols. 

Asia Market Size, Share and CAGR: Asia-Pacific market size is assessed near USD 0.54 billion in 2025, representing about 33% share of the global disposable hemoperfusion market, with an indicative CAGR near 10.5% reflecting rapid adoption. 

Asia - Major Dominant Countries in the “Disposable Hemoperfusion Market”

• China — Market Size ~USD 0.49 billion, Share ~29%, CAGR ~11.5%, driven by mass distribution of resin and dual-layered cartridges and large hospital integration in 2024.
• Japan — Market Size ~USD 0.10 billion, Share ~6%, CAGR ~6.5%, supported by domestic manufacturers shipping multi-million unit volumes in 2024. 
• India — Market Size ~USD 0.05 billion, Share ~3%, CAGR ~12.0%, with increasing approvals and tertiary hospital pilots in 2024. 
• Australia — Market Size ~USD 0.03 billion, Share ~1.8%, CAGR ~7.0%, used in liver support and ICU protocols in major hospitals. 
• South Korea — Market Size ~USD 0.02 billion, Share ~1.2%, CAGR ~7.5%, supported by advanced liver and transplant centers.

Middle East & Africa 

Middle East & Africa (MEA) represents an emerging and heterogeneous market for disposable hemoperfusion cartridges, with demand concentrated in medical hubs and tertiary care centers in the Gulf Cooperation Council (GCC) and select African referral hospitals. Adoption in MEA accelerated modestly in 2024 as several regional hospitals initiated hemoperfusion protocols for severe intoxication and liver-support cases; specialized private hospital chains in the GCC reported procurement increases for disposable cartridges and partnered with manufacturers for training programs covering over 200 clinicians in 2024. Public hospitals in North Africa and parts of sub-Saharan Africa showed pilot engagements, often supported by international aid programs and localized clinical trials focusing on toxin-removal applications. 

Middle East & Africa Market Size, Share and CAGR: MEA market size is estimated at approximately USD 0.08 billion in 2025, representing about 5% share of the global disposable hemoperfusion market, with an indicative CAGR near 8.0% as regional capacities scale. 

Middle East and Africa - Major Dominant Countries in the “Disposable Hemoperfusion Market”

• Saudi Arabia — Market Size ~USD 0.03 billion, Share ~1.8%, CAGR ~8.5%, driven by tertiary hospital procurement and government hospital modernization programs in 2024. 
• United Arab Emirates — Market Size ~USD 0.02 billion, Share ~1.2%, CAGR ~8.0%, supported by private hospital chains and clinical training partnerships. 
• South Africa — Market Size ~USD 0.01 billion, Share ~0.6%, CAGR ~7.0%, reflecting limited adoption in referral hospitals and pilot programs. 
• Egypt — Market Size ~USD 0.01 billion, Share ~0.6%, CAGR ~7.5%, with emerging toxicology center interest and selective tertiary hospital uptake.
• Kuwait — Market Size ~USD 0.005 billion, Share ~0.3%, CAGR ~7.0%, supported by targeted public hospital procurement. 

List of Top Disposable Hemoperfusion Market Companies

• Tianjin Zibo High Technology
• CytoSorbents
• Baxter International
• Jafron Biomedical
• Kaneka Pharma
• Biosun Corporation
• Asahi Kasei Corporation
• Kangbei Medical Device
• Aier
• Toray Medical

Top 2 Companies with highest share

• CytoSorbents — CytoSorbents has expanded clinical reach into intensive care and cardiac surgery units with adoption programs spanning thousands of hospital sites; public quarterly data show product sales growth rates of +14% (Q1 2024) and +10% (Q2 2024) versus prior year periods.
• Jafron Biomedical — Jafron’s resin hemoadsorption technology is supported by large clinical programs (a 4-year multi-center study across 37 clinical centers) and long-running use cases since its initial resin cartridge development in 1999, with clinical bead sizes and pore ranges documented .

Investment Analysis and Opportunities

Investment interest in disposable hemoperfusion is driven by rising hospital adoption and a pipeline of next-generation cartridges; more than 10,000 hospitals globally engaged with hemoperfusion protocols or pilots by 2024, and Asia-Pacific reported thousands of new resin integrations in 2024, creating multiple B2B procurement opportunities for manufacturers and distributors. Strategic investors are evaluating supply-chain localization—shortening lead times by up to 15% in 2024 through local sourcing of housings and adsorbents—which improves margins and reduces stockouts for hospital networks.

Public-private pilots and government reimbursement pilots funded roughly dozens of multi-hospital programs in 2024, enabling manufacturers to sign multi-year supply contracts often covering hundreds of thousands of disposable cartridges. Capital deployment cases include increased manufacturing capacity (expansions adding tens of thousands of cartridges per month), clinical trial sponsorships (multi-center trials spanning 20–40 hospitals), and partnership deals for clinician training programs reaching hundreds of ICU staff per region. 

New Product Development

Manufacturers focused on multi-adsorbent and biocompatible membrane improvements launched several new disposable cartridge platforms between 2023 and 2025, including dual-layer and coated-bead designs that improve target molecule capture and reduce blood trauma. Reported product characteristics include bead mean diameters near 0.8 mm, pore cutoffs ranging from 50 Da to 60 kDa for selective adsorption, and multi-adsorbent layering that enables simultaneous removal of hydrophobic toxins and inflammatory cytokines in a single pass.

Development pipelines added devices optimized for sepsis cytokine adsorption, hepatic toxin removal, and targeted drug clearance, each validated in pilot programs spanning 10–40 hospitals and in some cases evaluated in multi-center studies over 12–48 months. Manufacturers reported production scale-ups adding tens of thousands of cartridges per quarter to meet hospital demand spikes, and some introduced cartridges with standardized extracorporeal connectors that reduced set-up times by up to 20% in clinical simulation trials.

Five Recent Developments 

• CytoSorbents — Q1/Q2 2024 operational momentum: Product sales improved year-over-year with Q1 2024 product sales rising +14% and Q2 2024 product sales rising +10% versus prior year quarters, reflecting expanded hospital program adoption in 2024. 
• Jafron — Multi-center clinical program (2023 onward): A four-year multicenter hemoperfusion study involved 37 clinical medical centers to evaluate resin hemoadsorption in chronic hemodialysis and related indications.
• Manufacturer product launches — 2024–2025: Several manufacturers introduced dual-layer / multi-adsorbent cartridges between 2023 and 2025, with pilot distributions to hundreds of hospitals and production scale-ups adding tens of thousands of cartridges to supply chains. 
• Clinical adoption increases — Asia-Pacific 2024: Regional reports cite thousands of hospital integrations for resin-based hemoperfusion platforms during 2024, driving significant unit demand and broader B2B procurement activity across the region. 
• Regulatory and guideline updates — 2023–2025: National clinical societies and hospital networks in multiple regions updated protocols to include targeted hemoperfusion for hepatic encephalopathy.

Report Coverage of Disposable Hemoperfusion Market

This report covers the disposable hemoperfusion market across 8 major sections and provides B2B-oriented analytics for procurement, manufacturing and clinical adoption. The scope includes market segmentation by type (2 types), application (5 applications), and regional performance across 5 regions, plus profiles for 10 leading manufacturers. The document contains quantitative datasets such as unit shipment volumes, hospital adoption counts, and pilot program sizes—datasets referencing thousands to millions of disposable cartridges and targeting multi-hospital roll-outs, multi-center clinical trials (20–40 centers), and production capacity metrics measured in tens of thousands of units per quarter. Coverage includes supply-chain mapping (lead-time change metrics, e.g., 15% lead-time improvement after local sourcing), clinical outcomes (adverse event percentage reductions up to 35% in updated cartridges).

Disposable Hemoperfusion Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1924.7 Million in 2026
Market Size Value By	USD 7308.89 Million by 2035
Growth Rate	CAGR of 15.88% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Charcoal Hemoperfusion Certain Resins Hemoperfusion By Application : Overdose Specific Intoxications Certain Autoimmune Diseases Hepatic Encephalopathy Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample